InflaRx N-V is a biotechnology business based in the US. InflaRx N-V shares (IFRX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.73 – an increase of 33.08% over the previous week. InflaRx N-V employs 74 staff and has a trailing 12-month revenue of around $165,789.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $1.73 |
|---|---|
| 52-week range | $0.82 - $2.82 |
| 50-day moving average | $1.25 |
| 200-day moving average | $1.71 |
| Wall St. target price | $9.64 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.89 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.73 from 2025-05-02
| 1 week (2025-04-25) | 33.08% |
|---|---|
| 1 month (2025-04-04) | 71.29% |
| 3 months (2025-02-04) | -29.96% |
| 6 months (2024-11-04) | 10.90% |
| 1 year (2024-05-03) | 25.36% |
|---|---|
| 2 years (2023-05-03) | -61.89% |
| 3 years (2022-05-03) | 4.22% |
| 5 years (2020-05-01) | 6.99 |
| Revenue TTM | $165,789 |
|---|---|
| Operating margin TTM | 2308149.2% |
| Gross profit TTM | $-3,151,250 |
| Return on assets TTM | -33.77% |
| Return on equity TTM | -56.18% |
| Profit margin | 0% |
| Book value | $1.04 |
| Market Capitalization | $125.3 million |
TTM: trailing 12 months
We're not expecting InflaRx N-V to pay a dividend over the next 12 months.
Over the last 12 months, InflaRx N-V's shares have ranged in value from as little as $0.8238 up to $2.815. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while InflaRx N-V's is 2.218. This would suggest that InflaRx N-V's shares are significantly more volatile than the average for this exchange and represent a higher risk.
InflaRx N. V. , a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co.
Track the progress of the S&P 500 stocks to make more informed investment decisions.
See our picks for the best brokers for trading S&P 500 stocks, ETFs, options and futures.
These are the stocks to buy when you don’t have much to spend.
Explore the best bonuses for opening a new brokerage account.
Stock lending allows investors to loan out their existing stocks, although it has both advantages and disadvantages.
Compare pros, cons, research tools and reviews for these two trading platforms.
Some of the best trading apps like Robinhood are SoFi, Tastytrade, Public, eToro, Acorns, Interactive Brokers, E*TRADE and more.
Compare pros, cons, research tools and reviews for these two trading platforms.
SoFi Invest is a no-fee commissions platform with both active and automated investment accounts.
Webull is a broker with zero-commission trading and a suite of tools to help you invest.